Latest Advances

  • Condition: Acute Encephalitic Syndrome Induced by Scleromyxedema
  • Journal: The American journal of the medical sciences
  • Treatment Used: Intravenous Immunoglobulin
  • Number of Patients: 1
  • Published —
This case report describes a 62-year-old female patient who developed acute encephalitic syndrome induced by scleromyxedema (skin disease) treated with intravenous immunoglobulin.
  • Condition: Scleromyxedema
  • Journal: Dermatologic therapy
  • Treatment Used: Intravenous immunoglobulin
  • Number of Patients: 1
  • Published —
The study researched the use of intravenous immunoglobulin for patients with scleromyxedema with multiple systemic involvement.
  • Condition: Scleromyxedema (SM) in Patient with Thyroid Disease
  • Journal: Cutis
  • Treatment Used: Intravenous Immunoglobulin (IVIg) and Lenalidomide
  • Number of Patients: 1
  • Published —
This case report describes a patient with uncontrolled hypothyroidism due to Hashimoto thyroiditis who developed scleromyxedema (skin disorder; SM) treated with intravenous immunoglobulin (IVIg) and lenalidomide.
  • Condition: Monoclonal gammopathy-associated scleromyxedema
  • Journal: Blood
  • Treatment Used: Plasma cell-directed therapies
  • Number of Patients: 33
  • Published —
The study researched the outcomes of plasma cell-directed therapies for patients with monoclonal gammopathy-associated scleromyxedema.
  • Condition: Scleromyxedema with Pulmonary Hypertension and Multiple Myeloma
  • Journal: BMC pulmonary medicine
  • Treatment Used: Bortezomib, Cyclophosphamide, and Dexamethasone
  • Number of Patients: 1
  • Published —
This case report describes a patient with scleromyxedema alongside a severe pulmonary hypertension and multiple myeloma that was treated using a combination bortezomib, cyclophosphamide, and dexamethasone therapy.
  • Condition: Scleromyxedema (SMX)
  • Journal: Arthritis care & research
  • Treatment Used: Intravenous Immunoglobulin (IVIG)
  • Number of Patients: 15
  • Published —
This study explored whether immunoglobulin (IVIG) would introduce a measurable biologic effect corresponding with clinical improvement in scleromyxedema (SMX), a rare systemic sclerosis mimic.
Showing 1-6 of 6